Stonegate Updates Coverage on NZX Limited (NZSE: NZX) 2H25
NZX reported 2H26 revenue, operating profit, and EBITDA of $67.2M, $17.7M, and $27.6M, respectively. This compares to our estimates of $68.8M, $16.2M, and $27.7M. Revenue was modestly below our forecast, while profitability was broadly in line. The variance was mainly driven by softer market activity amid lingering macro uncertainty, which we expect to improve over […]
Stonegate Capital Partners Updates Coverage on Valens Semiconductor Ltd. (NYSE:VLN) Q425
Valens Semiconductor posted 4Q25 revenue of $19.4M, significantly above guidance of $18.2–$18.9M, marking its seventh consecutive quarter of growth and up from $17.3M in 3Q25 and $16.7M in 4Q24. GAAP gross margin was 60.5% (nonGAAP 63.9%), exceeding guidance while easing slightly from 63.0% in 3Q25. Adjusted EBITDA loss of $(4.3)M was within guidance of $(4.6)-$(4.2)M […]
Stonegate Capital Partners Updates Coverage on Electro Optics Systems Holdings Ltd (ASX: EOS) 4Q 2025
EOS reported FY25 revenue, gross margin, and EBITDA of $126.3M, 63%, and $(24.4M), respectively, with the revenue decline driven by the EM Solutions divestment and order timing shifting later in FY25, expected to convert into FY26. EOS ended the year with $106.9M of cash and strong order momentum with 18 contracts signed worth ~$420M and […]
Stonegate Capital Partners Updates Coverage on Armour Residential REIT, Inc. (NYSE: ARR) 2025 Q4
The Company ended the quarter with interest income, net income to common, and diluted EPS of $236.5M, $208.7M, and $1.86. This was a year over year increase of 55.1%, $258.1M and $2.69 respectively. This was primarily driven by the strong growth in average interest income on interest earning assets while interest cost on average interest-bearing […]
Stonegate Capital Partners Updates Coverage on Gladstone Commercial Corp. (NasdaqGS: GOOD) 2025 Q4
In the fourth quarter of 2025, Gladstone Commercial Corp. maintained its disciplined portfolio management approach. The Company ended the quarter with 151 properties across 27 states, comprised of 17.7M square feet of rentable space. During FY25, GOOD executed its capital recycling strategy by selling two non-core properties, for an aggregate amount of $8.0M and completed […]
Stonegate Updates Coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL) 2Q 2026
Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both lowand high-dose IHL-42X achieved statistically significant reductions in ApneaHypopnoea Index (AHI) versus placebo, with maximum AHI reductions of up to 83% in the high-dose arm. Exit interviews showed […]
Stonegate Updates Coverage on Third Coast Bancshares, Inc. (NYSE:TCBX) Q4 2025
For 4Q25, Third Coast reported net income of $17.9M, compared to $18.1M in 3Q25 and $13.7M in 4Q24, equal to basic and diluted EPS of $1.21 and $1.02, respectively. The modest Q/Q decline was primarily driven by merger-related legal/professional expenses and higher salaries/benefits, partially offset by higher NII and an increase in non-margin loan fees. […]
Stonegate Capital Partners Updates Coverage on Provident Financial Services Inc (NYSE: PFS) 2025 Q4
Provident Financial Services delivered another strong quarter of expanding profitability and continued operating momentum. Net income increased to $83.4M, for an EPS of $0.64, driving a 1.34% ROAA. Revenue reached a third consecutive quarterly record at $225.7M, supported by record net interest income of $197.4M and record noninterest income of $28.3M, reflecting the Company’s ability […]
Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB)
AB Science is a late-stage biotech advancing masitinib, an oral, selective tyrosine kinase inhibitor designed to modulate maladaptive neuroinflammation through mast-cell and microglia/macrophage pathways. The Company is positioning masitinib as an add-on therapy across ALS, progressive MS, and AD, while maintaining earlier-stage upside through AB8939 in AML. The combination of a treatment for ALS along […]
Stonegate Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) FY26 Q3
Burcon’s Galesburg production facility represents a pivotal transition from development-stage operations to commercial scale, with 3Q26 revenue of $739,000 reflecting approximately 107% quarter-overquarter growth driven by protein sales and production activity at the site. Notably, the Company entered CY2025 without a production facility and exited the year meeting its revenue target, underscoring the speed of […]